A Phase 2 Bridging Study to Assess the New Formulation of ETVAX

PHASE2CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

November 8, 2021

Primary Completion Date

October 20, 2022

Study Completion Date

October 20, 2022

Conditions
Healty VolunteersPreventable Disease, Vaccine
Interventions
BIOLOGICAL

Etvax

"Preparation of complete Wet formulation. The vaccine supplied as a liquid, is mixed with the 150 ml of sodium bicarbonate buffer solution on the day of preparation for use on dosing day.~Just prior to administration 10 µg of dmLT is added by pipette (50 µl)."

BIOLOGICAL

Etvax

Preparation of partially dry formulation. The partially dry formulation of vaccine is prepared by adding the effervescent powder containing the dmLT and LCTBA to 150 ml of water. After mixing, the content of the vaccine vial is added to the mixture and the vaccine is administered to the volunteer within 30 minutes after adding the buffer powder to the water.

Trial Locations (1)

41346

Clinical Trial Center, CTC, Gothenburg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Göteborg University

OTHER

collaborator

Aurevia

INDUSTRY

collaborator

Sahlgrenska University Hospital

OTHER

lead

Scandinavian Biopharma AB

INDUSTRY

NCT05178134 - A Phase 2 Bridging Study to Assess the New Formulation of ETVAX | Biotech Hunter | Biotech Hunter